Increased induction of antitumor response by exosomes derived from interleukin-2 gene-modified tumor cells
暂无分享,去创建一个
Qingqing Wang | Zhijian Cai | Yunshan Yang | Xuetao Cao | Jianli Wang | Qingqing Wang | Yangxin Fu | Xuetao Cao | Jianli Wang | Fangming Xiu | Zhijian Cai | Yunshan Yang | Fangming Xiu | YangXin Fu
[1] Laurence Zitvogel,et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell derived exosomes , 1998, Nature Medicine.
[2] M. Lotze,et al. Th1/Th2 balance in cancer, transplantation and pregnancy , 2004, Springer Seminars in Immunopathology.
[3] X. Cao,et al. Efficient inducation of local and systemic antitumor immune response by liposome-mediated intratumoral co-transfer of interleukin-2 gene and interleukin-6 gene. , 1999, Journal of experimental & clinical cancer research : CR.
[4] S. Ma,et al. Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity. , 1998, Journal of immunology.
[5] J. Le Pecq,et al. A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer , 2005, Journal of Translational Medicine.
[6] M. Atkins,et al. Update on the Role of Interleukin 2 and Other Cytokines in the Treatment of Patients with Stage IV Renal Carcinoma , 2004, Clinical Cancer Research.
[7] yang-xin fu,et al. Tumor-infiltrating T lymphocytes: friends or foes? , 2006, Laboratory Investigation.
[8] L. Zitvogel,et al. Dendritic cell-derived exosomes as cell-free peptide-based vaccines. , 2005, Critical reviews in immunology.
[9] M. Guo,et al. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer. , 2002, Cancer research.
[10] Laurence Zitvogel,et al. Tumor-derived exosomes are a source of shared tumor rejection antigens for CTL cross-priming , 2001, Nature Medicine.
[11] H. Hamada,et al. Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100 , 2002, Gene Therapy.
[12] P. Paz,et al. Exosomes as a Tumor Vaccine: Enhancing Potency Through Direct Loading of Antigenic Peptides , 2003, Journal of immunotherapy.
[13] C. Melief,et al. B lymphocytes secrete antigen-presenting vesicles , 1996, The Journal of experimental medicine.
[14] Olivier Lantz,et al. Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial , 2005, Journal of Translational Medicine.
[15] J. Bystryn,et al. Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice , 2006, Cancer Immunology, Immunotherapy.
[16] Nan Li,et al. Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine. , 2005, Cancer research.
[17] P. Ricciardi-Castagnoli,et al. IL-2 mediates adjuvant effect of dendritic cells. , 2002, Trends in immunology.
[18] Taoyong Chen,et al. More Efficient Induction of HLA-A*0201-Restricted and Carcinoembryonic Antigen (CEA)–Specific CTL Response by Immunization with Exosomes Prepared from Heat-Stressed CEA-Positive Tumor Cells , 2005, Clinical Cancer Research.
[19] N. Restifo,et al. The future of interleukin-2: enhancing therapeutic anticancer vaccines. , 2000, The cancer journal from Scientific American.
[20] M. Tsan,et al. Cytokine function of heat shock proteins. , 2004, American journal of physiology. Cell physiology.
[21] M. Marra,et al. New pharmacokinetic and pharmacodynamic tools for interferon-alpha (IFN-α) treatment of human cancer , 2004, Cancer Immunology, Immunotherapy.
[22] M. Levitt,et al. Interleukin‐2 induces development of dendritic cells from cord blood CD34+ cells , 1998, Journal of leukocyte biology.
[23] Simon C Watkins,et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. , 2004, Blood.
[24] Taoyong Chen,et al. Novel heat shock protein Hsp70L1 activates dendritic cells and acts as a Th1 polarizing adjuvant. , 2004, Blood.
[25] L. Zitvogel,et al. Exosomes as Potent Cell-Free Peptide-Based Vaccine. II. Exosomes in CpG Adjuvants Efficiently Prime Naive Tc1 Lymphocytes Leading to Tumor Rejection 1 , 2004, The Journal of Immunology.
[26] M. Colombo,et al. Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. , 2005, Cancer research.
[27] J. Mulé,et al. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[28] T. Wan,et al. Enhanced antitumor immune responses of IL-2 gene-modified tumor vaccine by combination with IL-1 and low dose cyclophosphamide. , 1999, Journal of experimental & clinical cancer research : CR.
[29] T. Kuzel,et al. Interleukin-2 in the treatment of renal cell carcinoma and malignant melanoma. , 2005, Cancer treatment and research.
[30] C. Gross,et al. Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. , 2005, Cancer research.
[31] Laurence Zitvogel,et al. Exosomes: composition, biogenesis and function , 2002, Nature Reviews Immunology.
[32] S. Koyasu,et al. Expression of functional IL‐2 receptors on mature splenic dendritic cells , 2000, European journal of immunology.
[33] C. Théry,et al. Indirect activation of naïve CD4+ T cells by dendritic cell–derived exosomes , 2002, Nature Immunology.